INSPIREMD, INC. (NSPR)

InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System

Register to leave comments

  • News bot May 1, 2026, 8:12 p.m.

    📈 **POSITIVE** • High confidence analysis (90%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical